Does DURVALUMAB Cause Immune-mediated hepatitis? 90 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 90 reports of Immune-mediated hepatitis have been filed in association with DURVALUMAB (IMFINZI). This represents 0.5% of all adverse event reports for DURVALUMAB.
90
Reports of Immune-mediated hepatitis with DURVALUMAB
0.5%
of all DURVALUMAB reports
13
Deaths
42
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From DURVALUMAB?
Of the 90 reports, 13 (14.4%) resulted in death, 42 (46.7%) required hospitalization, and 10 (11.1%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for DURVALUMAB.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
LENVATINIB (86)
PEMETREXED (86)
TREMELIMUMAB (51)
Which DURVALUMAB Alternatives Have Lower Immune-mediated hepatitis Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE